Cargando…

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice

BACKGROUND: Addition of docetaxel to androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been proved to be effective with an overall survival (OS) benefit in phase III clinical trials. The effectiveness of docetaxel with ADT in the general...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lendorf, Maria Elisabeth, Petersen, Peter Meidahl, Svendsen, Andrea Steen, Lindberg, Henriette, Brasso, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Prostate Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317901/ https://www.ncbi.nlm.nih.gov/pubmed/34337492 http://dx.doi.org/10.1016/j.euros.2020.12.006

Ejemplares similares

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
por: Gongora, Magdalena, et al.
Publicado: (2022)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2021)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
por: Lumen, Nicolaas, et al.
Publicado: (2021)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2022)

Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
por: Jasu, Juho, et al.
Publicado: (2021)

A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression
por: Wänman, Johan, et al.
Publicado: (2022)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)

Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment
por: Menges, Dominik, et al.
Publicado: (2023)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)
por: Woo, Henry H., et al.
Publicado: (2022)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
por: Remmers, Sebastiaan, et al.
Publicado: (2022)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study
por: Norris, Joseph M., et al.
Publicado: (2021)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
por: Kelly, Brian D., et al.
Publicado: (2023)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score–matching Study
por: Wei, Yongbao, et al.
Publicado: (2022)

Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
por: Aerts, Jan, et al.
Publicado: (2023)

Accuracy of Prostate Magnetic Resonance Imaging: Reader Experience Matters
por: Kang, Hyunseon C., et al.
Publicado: (2021)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021)

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study
por: Tosoian, Jeffrey J., et al.
Publicado: (2021)

Role of the Prostate Imaging Quality PI-QUAL Score for Prostate Magnetic Resonance Image Quality in Pathological Upstaging After Radical Prostatectomy: A Multicentre European Study
por: Windisch, Olivier, et al.
Publicado: (2022)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
por: Nordström, Tobias, et al.
Publicado: (2021)

Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer
por: Axén, Elin, et al.
Publicado: (2021)

Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race
por: Kensler, Kevin H., et al.
Publicado: (2022)

Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes
por: Ahlberg, Mats S., et al.
Publicado: (2023)

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes
por: Ben-Salem, Salma, et al.
Publicado: (2020)

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
por: Barrett, Tristan, et al.
Publicado: (2022)

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
por: Andersson, Joel, et al.
Publicado: (2022)

Clinical Value of a Routine Urine Culture Prior to Transrectal Prostate Biopsy
por: Örtegren, Joakim, et al.
Publicado: (2022)

Side-specific, Microultrasound-based Nomogram for the Prediction of Extracapsular Extension in Prostate Cancer
por: Pedraza, Adriana M., et al.
Publicado: (2022)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
por: Hogenhout, Renée, et al.
Publicado: (2022)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Autio, Karen A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n4qf1cqtqtcb6r11jgbala34sb